查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1446557

心臟病学和神经病学 IVD 市场规模、份额和趋势分析报告：按产品类型、技术、最终用途、地区和细分市场进行预测，2024-2030 年

IVD In Cardiology And Neurology Market Size, Share & Trends Analysis Report By Product Type (Instruments, Reagents & Consumables), By Technology, By End-use, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 125 Pages | 商品交期: 2-10个工作天内

价格

心臟病学和神经病学 IVD 市场的成长和趋势：

Grand View Research, Inc.最新报告显示，预计到2030年，全球心臟和神经IVD市场规模将达到305.4亿美元，2024年至2030年复合年增长率为9.44%。

市场成长的主要驱动力是由于老年人口的增加而导致心血管和神经病变的盛行率不断增加。根据世界心臟联盟发表的论文，2023年心血管疾病（CVD）将成为全球主要死亡原因，预计2021年将有2,050万人死亡。此外，已发现神经系统疾病影响全球15%的人口。

将新药或现有药物与生物标记结合的创新治疗方法不断被公布。例如，透过测量分子来追踪大脑健康的生物标记现在被用于治疗神经系统疾病。最近的生物标记进展，例如生物标记特征，正在增强神经系统疾病的治疗。其结果是早期诊断、快速药物开发和非侵入性检测。此外，数位生物标记为许多製药公司提供了背景和补充讯息，以做出临床试验决策。例如，IXICO Plc 与领先的生物製药公司合作，对数位生物标记进行临床验证并将其用于临床试验。

此外，用于诊断 AD 和轻度创伤性脑损伤等适应症的 BBBM 测试的开发和推出也促进了市场的成长。例如，2020 年 3 月，NIH 资助的研究人员开发了一种基于血液的测试，可以检测磷酸化Tau -181 (ptau181)，这表阿兹海默症的存在。与现有的脑部影像检查和脑脊髓液测试相比，这种方法成本更低，侵入性也更低。同样，2021 年 1 月，雅培推出了首个针对创伤性脑损伤（包括脑震盪）的快速血液检测。此测试可测量脑外伤后血液中的某些蛋白质，如果测试结果为阴性，可用于排除电脑断层扫描的必要性。

此外，IVD 在诊断和监测各种疾病的各个临床领域中变得越来越重要。增加针对心血管和神经系统疾病的新型 IVD 解决方案的可用性是预计推动市场成长的关键因素之一。例如，2023年10月，迈瑞宣布扩大心臟生物标记产品组合，推出两种新型高灵敏度NT-proBNP和肌钙蛋白i (hs-cTnI)心臟生物标记。透过此次推出，该公司旨在透过创新技术加强现有产品组合併使其多样化，以更好地诊断和管理 CVD。此外，2023 年 7 月，Quest Diagnostics 宣布推出阿兹海默症AD-Detect 测试，这是第一个帮助人们了解阿兹海默症症潜在风险的消费者测试。

心臟病学和神经病学 IVD 市场报告亮点

  • 试剂和耗材领域预计将引领市场，并在 2024 年至 2030 年实现最快的复合年增长率。这是由于领先公司为开发新型生物标记套件而进行的广泛研究和开发倡议。
  • 由于新型免疫诊断解决方案的研发不断增加，免疫测量领域在 2023 年引领市场。
  • 由于先进和创新的分子诊断仪器的发展，分子诊断领域预计将从 2024 年到 2030 年以最快的复合年增长率增长。
  • 由于领先的医疗机构提供优质医疗保健以向医院提供创新设备的总体趋势，医院最终用途细分市场将在 2023 年引领市场。
  • 由于先进的医疗基础设施、目标疾病盛行率上升以及有利的法规环境等因素，北美在2023年将主导全球市场。

目录

第一章调查方法和范围

第 2 章执行摘要

第三章心臟病学和神经病学 IVD 市场：变数、趋势和范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 心臟病学和神经病学 IVD 市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析
    • 价格分析
    • 体积分析（设备）

第四章心臟病和神经病学IVD市场：产品类型估算和趋势分析

  • 全球心臟病学和神经学 IVD 市场：产品类型仪表板
  • 心臟病学和神经病学 IVD 的全球市场：产品类型变化分析
  • 全球心臟病学/神经学 IVD 市场，按产品类型分類的收益
  • 装置
  • 试剂/耗材
  • 软体服务

第五章心臟病和神经病学IVD市场：技术评估和趋势分析

  • 全球心臟病学和神经病学 IVD 市场：技术仪表板
  • 心臟病学和神经病学 IVD 的全球市场：技术波动分析
  • 全球心臟病学和神经病学 IVD 市场（按技术和收益划分）
  • 免疫测量
  • 分子诊断
  • 血
  • 其他的

第六章心臟病学和神经病学的 IVD 市场：最终用途估计和趋势分析

  • 全球心臟病学和神经病学 IVD 市场：最终用途仪表板
  • 全球心臟病学和神经病学 IVD 市场：最终用途变化分析
  • 全球心臟病学/神经学 IVD 市场，按最终用途、收益
  • 医院
  • 临床实验室
  • 其他的

第 7 章 心臟病学和神经病学 IVD 市场：区域估计和趋势分析，按产品类型、技术、最终用途

  • 区域仪表板
  • 2018-2030年市场规模及预测趋势分析
  • 北美洲
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 中东/非洲

第八章 竞争形势

  • 主要市场参与企业的最新趋势和影响分析
  • 公司/竞争对手分类
  • 供应商形势
    • Thermo Fisher Scientific Inc.
    • F. Hoffmann-La Roche Ltd
    • Sysmex Corporation
    • Siemens Healthineers AG
    • Quest Diagnostics Incorporated
    • Abbott
    • BD（Becton Dickinson）
    • Bio-Rad Laboratories, Inc.
    • Beckman Coulter, Inc.
Product Code: GVR-4-68040-204-5

IVD In Cardiology And Neurology Market Growth & Trends:

The global IVD in cardiology and neurology market size is anticipated to reach USD 30.54 billion by 2030, registering a CAGR of 9.44% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market growth is primarily driven by the increasing prevalence of cardiovascular and neurological disorders aided by the growing geriatric population. According to an article published by the World Heart Federation, in 2023, cardiovascular diseases (CVDs) are the leading cause of death worldwide, with an estimated deaths registered being 20.5 million in 2021. Moreover, neurological disorders are found to affect 15% of the total population globally.

Innovative treatments that combine new or existing medicines with biomarkers are continuously being launched. For instance, currently, biomarkers are used for the treatment of neurological diseases to track brain health by measuring molecules. Recent progressions in biomarkers, such as biomarker signatures, are enhancing the treatment of neurological diseases. This has resulted in early diagnosis, faster drug development, and noninvasive testing. Moreover, digital biomarkers offer numerous pharmaceutical companies contextual and supplemental information to conclude clinical trial decisions. For instance, IXICO Plc is collaborating with major biopharmaceutical firms to authenticate clinically digital biomarkers and use them in clinical trials.

Moreover, the development and introduction of BBBM tests for the diagnosis of indications, such as AD & mild traumatic brain injury, among others, are contributing to market growth. For instance, in March 2020, NIH-funded researchers developed a blood-based test for detecting phosphorylated-tau-181 (ptau181), indicating Alzheimer's disease presence. This approach is less costly and invasive than the existing brain imaging & spinal fluid tests. Similarly, in January 2021, Abbott introduced the first rapid blood test for traumatic brain injury, including concussion. This test measures a particular protein that is found in the blood after a traumatic brain injury and can be used to rule out the need for CT scanning in case of negative test results.

Furthermore, IVDs are gaining increasing importance across various clinical fields for the diagnosis and monitoring of various diseases. A rise in the availability of novel IVD solutions for cardiovascular and neurological disorders is one of the major drivers anticipated to boost market growth. For instance, in October 2023, Mindray announced the expansion of its cardiac biomarker portfolio with the launch of two novel highly sensitive NT-proBNP and troponin I (hs-cTnI) cardiac biomarkers. With this launch, the company aims to enhance and diversify its existing portfolio with innovative technologies for better diagnosis and management of CVDs. Moreover, in July 2023, Quest Diagnostics announced the availability of the first test available for consumers, the AD-Detect Test for Alzheimer's Disease that helps in accessing the potential risk of developing Alzheimer's disease.

IVD In Cardiology And Neurology Market Report Highlights:

  • The reagents & consumables segment led the market and is anticipated to register the fastest CAGR from 2024 to 2030 owing to extensive R&D initiatives being undertaken by major players for the development of novel biomarker kits
  • The immunoassays segment led the market in 2023 due to the rising R&D about the development of novel immunological diagnostic solutions
  • The molecular diagnostic segment is anticipated to grow at the fastest CAGR from 2024 to 2030 owing to the development of advanced and innovative molecular diagnostics instruments
  • The hospitals end-use segment led the market in 2023 due to the popular trend of providing innovative devices in hospitals by key plato provideiding quality care
  • North America dominated the global market in 2023 owing to factors, such as advanced healthcare infrastructure, rising prevalence of target diseases, and favorable regulatory environment

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product Type
    • 1.2.2. Technology
    • 1.2.3. End-use
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product type and technology outlook
    • 2.2.2. End-use outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. In Vitro Diagnostics (IVD) in Cardiology and Neurology Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing prevalence of chronic diseases such as cardiovascular and neurological disorders
      • 3.2.1.2. Technological advancement
      • 3.2.1.3. Increasing demand for point-of-care diagnostics
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High cost of devices
      • 3.2.2.2. Stringent regulatory policies
  • 3.3. In Vitro Diagnostics (IVD) in Cardiology and Neurology Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
    • 3.3.3. Pricing Analysis
    • 3.3.4. Volume Analysis (Instruments)

Chapter 4. In Vitro Diagnostics (IVD) in Cardiology and Neurology Market: Product Type Estimates & Trend Analysis

  • 4.1. Global In Vitro Diagnostics (IVD) in Cardiology and Neurology Market: Product Type Dashboard
  • 4.2. Global In Vitro Diagnostics (IVD) in Cardiology and Neurology Market: Product Type Movement Analysis
  • 4.3. Global In Vitro Diagnostics (IVD) in Cardiology and Neurology Market by Product Type, Revenue
  • 4.4. Instruments
    • 4.4.1. Instruments market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Reagents & Consumables
    • 4.5.1. Reagents & consumables market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. Software and Services
    • 4.6.1. Software and services market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. In Vitro Diagnostics (IVD) in Cardiology and Neurology Market: Technology Estimates & Trend Analysis

  • 5.1. Global In Vitro Diagnostics (IVD) in Cardiology and Neurology Market: Technology Dashboard
  • 5.2. Global In Vitro Diagnostics (IVD) in Cardiology and Neurology Market: Technology Movement Analysis
  • 5.3. Global In Vitro Diagnostics (IVD) in Cardiology and Neurology Market by Technology, Revenue
  • 5.4. Immunoassays
    • 5.4.1. Immunoassays market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Molecular Diagnostics
    • 5.5.1. Molecular diagnostics market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. Hematology
    • 5.6.1. Hematology market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7. Others
    • 5.7.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. In Vitro Diagnostics (IVD) in Cardiology and Neurology Market: End-use Estimates & Trend Analysis

  • 6.1. Global In Vitro Diagnostics (IVD) in Cardiology and Neurology Market: End-use Dashboard
  • 6.2. Global In Vitro Diagnostics (IVD) in Cardiology and Neurology Market: End-use Movement Analysis
  • 6.3. Global In Vitro Diagnostics (IVD) in Cardiology and Neurology Market by End-use, Revenue
  • 6.4. Hospitals
    • 6.4.1. Hospitals market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Clinical Laboratories
    • 6.5.1. Clinical laboratories market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Others
    • 6.6.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. In Vitro Diagnostics (IVD) in Cardiology and Neurology Market: Regional Estimates & Trend Analysis by Product Type, Technology, and End-use

  • 7.1. Regional Dashboard
  • 7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.3. North America
    • 7.3.1. U.S.
      • 7.3.1.1. Key country dynamics
      • 7.3.1.2. Regulatory framework/ reimbursement structure
      • 7.3.1.3. Competitive scenario
      • 7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.2. Canada
      • 7.3.2.1. Key country dynamics
      • 7.3.2.2. Regulatory framework/ reimbursement structure
      • 7.3.2.3. Competitive scenario
      • 7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4. Europe
    • 7.4.1. UK
      • 7.4.1.1. Key country dynamics
      • 7.4.1.2. Regulatory framework/ reimbursement structure
      • 7.4.1.3. Competitive scenario
      • 7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.2. Germany
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Regulatory framework/ reimbursement structure
      • 7.4.2.3. Competitive scenario
      • 7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.3. France
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Regulatory framework/ reimbursement structure
      • 7.4.3.3. Competitive scenario
      • 7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.4. Italy
      • 7.4.4.1. Key country dynamics
      • 7.4.4.2. Regulatory framework/ reimbursement structure
      • 7.4.4.3. Competitive scenario
      • 7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.5. Spain
      • 7.4.5.1. Key country dynamics
      • 7.4.5.2. Regulatory framework/ reimbursement structure
      • 7.4.5.3. Competitive scenario
      • 7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.6. Norway
      • 7.4.6.1. Key country dynamics
      • 7.4.6.2. Regulatory framework/ reimbursement structure
      • 7.4.6.3. Competitive scenario
      • 7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.7. Sweden
      • 7.4.7.1. Key country dynamics
      • 7.4.7.2. Regulatory framework/ reimbursement structure
      • 7.4.7.3. Competitive scenario
      • 7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.8. Denmark
      • 7.4.8.1. Key country dynamics
      • 7.4.8.2. Regulatory framework/ reimbursement structure
      • 7.4.8.3. Competitive scenario
      • 7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Japan
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.2. China
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.3. India
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/ reimbursement structure
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.4. Australia
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Regulatory framework/ reimbursement structure
      • 7.5.4.3. Competitive scenario
      • 7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.5. South Korea
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Regulatory framework/ reimbursement structure
      • 7.5.5.3. Competitive scenario
      • 7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.6. Thailand
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Regulatory framework/ reimbursement structure
      • 7.5.6.3. Competitive scenario
      • 7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Latin America
    • 7.6.1. Brazil
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.2. Mexico
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.3. Argentina
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Regulatory framework/ reimbursement structure
      • 7.6.3.3. Competitive scenario
      • 7.6.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. MEA
    • 7.7.1. South Africa
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.2. Saudi Arabia
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.3. UAE
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.4. Kuwait
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. List of key distributors and channel partners
    • 8.3.2. Key customers
    • 8.3.3. Key company market share analysis, 2023
    • 8.3.4. Thermo Fisher Scientific Inc.
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Product benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. F. Hoffmann-La Roche Ltd
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Product benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. Sysmex Corporation
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Product benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. Siemens Healthineers AG
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Product benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. Quest Diagnostics Incorporated
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Product benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. Abbott
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Product benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. BD (Becton Dickinson)
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Product benchmarking
      • 8.3.10.4. Strategic initiatives
    • 8.3.11. Bio-Rad Laboratories, Inc.
      • 8.3.11.1. Company overview
      • 8.3.11.2. Financial performance
      • 8.3.11.3. Product benchmarking
      • 8.3.11.4. Strategic initiatives
    • 8.3.12. Beckman Coulter, Inc.
      • 8.3.12.1. Company overview
      • 8.3.12.2. Financial performance
      • 8.3.12.3. Product benchmarking
      • 8.3.12.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America in vitro diagnostics (IVD) in cardiology and neurology market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America in vitro diagnostics (IVD) in cardiology and neurology market, by product type, 2018 - 2030 (USD Million)
  • Table 4 North America in vitro diagnostics (IVD) in cardiology and neurology market, by technology, 2018 - 2030 (USD Million)
  • Table 5 North America in vitro diagnostics (IVD) in cardiology and neurology market, by end-use, 2018 - 2030 (USD Million)
  • Table 6 U.S. in vitro diagnostics (IVD) in cardiology and neurology market, by product type, 2018 - 2030 (USD Million)
  • Table 7 U.S. in vitro diagnostics (IVD) in cardiology and neurology market, by technology, 2018 - 2030 (USD Million)
  • Table 8 U.S. in vitro diagnostics (IVD) in cardiology and neurology market, by end-use, 2018 - 2030 (USD Million)
  • Table 9 Canada in vitro diagnostics (IVD) in cardiology and neurology market, by product type, 2018 - 2030 (USD Million)
  • Table 10 Canada in vitro diagnostics (IVD) in cardiology and neurology market, by technology, 2018 - 2030 (USD Million)
  • Table 11 Canada in vitro diagnostics (IVD) in cardiology and neurology market, by end-use, 2018 - 2030 (USD Million)
  • Table 12 Europe in vitro diagnostics (IVD) in cardiology and neurology market, by region, 2018 - 2030 (USD Million)
  • Table 13 Europe in vitro diagnostics (IVD) in cardiology and neurology market, by product type, 2018 - 2030 (USD Million)
  • Table 14 Europe in vitro diagnostics (IVD) in cardiology and neurology market, by technology, 2018 - 2030 (USD Million)
  • Table 15 Europe in vitro diagnostics (IVD) in cardiology and neurology market, by end-use, 2018 - 2030 (USD Million)
  • Table 16 Germany in vitro diagnostics (IVD) in cardiology and neurology market, by product type, 2018 - 2030 (USD Million)
  • Table 17 Germany in vitro diagnostics (IVD) in cardiology and neurology market, by technology, 2018 - 2030 (USD Million)
  • Table 18 Germany in vitro diagnostics (IVD) in cardiology and neurology market, by end-use, 2018 - 2030 (USD Million)
  • Table 19 UK in vitro diagnostics (IVD) in cardiology and neurology market, by product type, 2018 - 2030 (USD Million)
  • Table 20 UK in vitro diagnostics (IVD) in cardiology and neurology market, by technology, 2018 - 2030 (USD Million)
  • Table 21 UK in vitro diagnostics (IVD) in cardiology and neurology market, by end-use, 2018 - 2030 (USD Million)
  • Table 22 France in vitro diagnostics (IVD) in cardiology and neurology market, by product type, 2018 - 2030 (USD Million)
  • Table 23 France in vitro diagnostics (IVD) in cardiology and neurology market, by technology, 2018 - 2030 (USD Million)
  • Table 24 France in vitro diagnostics (IVD) in cardiology and neurology market, by end-use, 2018 - 2030 (USD Million)
  • Table 25 Italy in vitro diagnostics (IVD) in cardiology and neurology market, by product type, 2018 - 2030 (USD Million)
  • Table 26 Italy in vitro diagnostics (IVD) in cardiology and neurology market, by technology, 2018 - 2030 (USD Million)
  • Table 27 Italy in vitro diagnostics (IVD) in cardiology and neurology market, by end-use, 2018 - 2030 (USD Million)
  • Table 28 Spain in vitro diagnostics (IVD) in cardiology and neurology market, by product type, 2018 - 2030 (USD Million)
  • Table 29 Spain in vitro diagnostics (IVD) in cardiology and neurology market, by technology, 2018 - 2030 (USD Million)
  • Table 30 Spain in vitro diagnostics (IVD) in cardiology and neurology market, by end-use, 2018 - 2030 (USD Million)
  • Table 31 Denmark in vitro diagnostics (IVD) in cardiology and neurology market, by product type, 2018 - 2030 (USD Million)
  • Table 32 Denmark in vitro diagnostics (IVD) in cardiology and neurology market, by technology, 2018 - 2030 (USD Million)
  • Table 33 Denmark in vitro diagnostics (IVD) in cardiology and neurology market, by end-use, 2018 - 2030 (USD Million)
  • Table 34 Sweden in vitro diagnostics (IVD) in cardiology and neurology market, by product type, 2018 - 2030 (USD Million)
  • Table 35 Sweden in vitro diagnostics (IVD) in cardiology and neurology market, by technology, 2018 - 2030 (USD Million)
  • Table 36 Sweden in vitro diagnostics (IVD) in cardiology and neurology market, by end-use, 2018 - 2030 (USD Million)
  • Table 37 Norway in vitro diagnostics (IVD) in cardiology and neurology market, by product type, 2018 - 2030 (USD Million)
  • Table 38 Norway in vitro diagnostics (IVD) in cardiology and neurology market, by technology, 2018 - 2030 (USD Million)
  • Table 39 Norway in vitro diagnostics (IVD) in cardiology and neurology market, by end-use, 2018 - 2030 (USD Million)
  • Table 40 Asia Pacific in vitro diagnostics (IVD) in cardiology and neurology market, by region, 2018 - 2030 (USD Million)
  • Table 41 Asia Pacific in vitro diagnostics (IVD) in cardiology and neurology market, by product type, 2018 - 2030 (USD Million)
  • Table 42 Asia Pacific in vitro diagnostics (IVD) in cardiology and neurology market, by technology, 2018 - 2030 (USD Million)
  • Table 43 Aisa Pacific in vitro diagnostics (IVD) in cardiology and neurology market, by end-use, 2018 - 2030 (USD Million)
  • Table 44 China in vitro diagnostics (IVD) in cardiology and neurology market, by product type, 2018 - 2030 (USD Million)
  • Table 45 China in vitro diagnostics (IVD) in cardiology and neurology market, by technology, 2018 - 2030 (USD Million)
  • Table 46 China in vitro diagnostics (IVD) in cardiology and neurology market, by end-use, 2018 - 2030 (USD Million)
  • Table 47 Japan in vitro diagnostics (IVD) in cardiology and neurology market, by product type, 2018 - 2030 (USD Million)
  • Table 48 Japan in vitro diagnostics (IVD) in cardiology and neurology market, by technology, 2018 - 2030 (USD Million)
  • Table 49 Japan in vitro diagnostics (IVD) in cardiology and neurology market, by end-use, 2018 - 2030 (USD Million)
  • Table 50 India in vitro diagnostics (IVD) in cardiology and neurology market, by product type, 2018 - 2030 (USD Million)
  • Table 51 India in vitro diagnostics (IVD) in cardiology and neurology market, by technology, 2018 - 2030 (USD Million)
  • Table 52 India in vitro diagnostics (IVD) in cardiology and neurology market, by end-use, 2018 - 2030 (USD Million)
  • Table 53 South Korea in vitro diagnostics (IVD) in cardiology and neurology market, by product type, 2018 - 2030 (USD Million)
  • Table 54 South Korea in vitro diagnostics (IVD) in cardiology and neurology market, by technology, 2018 - 2030 (USD Million)
  • Table 55 South Korea in vitro diagnostics (IVD) in cardiology and neurology market, by end-use, 2018 - 2030 (USD Million)
  • Table 56 Australia in vitro diagnostics (IVD) in cardiology and neurology market, by product type, 2018 - 2030 (USD Million)
  • Table 57 Australia in vitro diagnostics (IVD) in cardiology and neurology market, by technology, 2018 - 2030 (USD Million)
  • Table 58 Australia in vitro diagnostics (IVD) in cardiology and neurology market, by end-use, 2018 - 2030 (USD Million)
  • Table 59 Thailand in vitro diagnostics (IVD) in cardiology and neurology market, by product type, 2018 - 2030 (USD Million)
  • Table 60 Thailand in vitro diagnostics (IVD) in cardiology and neurology market, by technology, 2018 - 2030 (USD Million)
  • Table 61 Thailand in vitro diagnostics (IVD) in cardiology and neurology market, by end-use, 2018 - 2030 (USD Million)
  • Table 62 Latin America in vitro diagnostics (IVD) in cardiology and neurology market, by region, 2018 - 2030 (USD Million)
  • Table 63 Latin America in vitro diagnostics (IVD) in cardiology and neurology market, by product type, 2018 - 2030 (USD Million)
  • Table 64 Latin America in vitro diagnostics (IVD) in cardiology and neurology market, by technology, 2018 - 2030 (USD Million)
  • Table 65 Latin America in vitro diagnostics (IVD) in cardiology and neurology market, by end-use, 2018 - 2030 (USD Million)
  • Table 66 Brazil in vitro diagnostics (IVD) in cardiology and neurology market, by product type, 2018 - 2030 (USD Million)
  • Table 67 Brazil in vitro diagnostics (IVD) in cardiology and neurology market, by technology, 2018 - 2030 (USD Million)
  • Table 68 Brazil in vitro diagnostics (IVD) in cardiology and neurology market, by end-use, 2018 - 2030 (USD Million)
  • Table 69 Mexico in vitro diagnostics (IVD) in cardiology and neurology market, by product type, 2018 - 2030 (USD Million)
  • Table 70 Mexico in vitro diagnostics (IVD) in cardiology and neurology market, by technology, 2018 - 2030 (USD Million)
  • Table 71 Mexico in vitro diagnostics (IVD) in cardiology and neurology market, by end-use, 2018 - 2030 (USD Million)
  • Table 72 Argentina in vitro diagnostics (IVD) in cardiology and neurology market, by product type, 2018 - 2030 (USD Million)
  • Table 73 Argentina in vitro diagnostics (IVD) in cardiology and neurology market, by technology, 2018 - 2030 (USD Million)
  • Table 74 Argentina in vitro diagnostics (IVD) in cardiology and neurology market, by end-use, 2018 - 2030 (USD Million)
  • Table 75 MEA in vitro diagnostics (IVD) in cardiology and neurology market, by region, 2018 - 2030 (USD Million)
  • Table 76 MEA in vitro diagnostics (IVD) in cardiology and neurology market, by product type, 2018 - 2030 (USD Million)
  • Table 77 MEA in vitro diagnostics (IVD) in cardiology and neurology market, by technology, 2018 - 2030 (USD Million)
  • Table 78 MEA in vitro diagnostics (IVD) in cardiology and neurology market, by end-use, 2018 - 2030 (USD Million)
  • Table 79 South Africa in vitro diagnostics (IVD) in cardiology and neurology market, by product type, 2018 - 2030 (USD Million)
  • Table 80 South Africa in vitro diagnostics (IVD) in cardiology and neurology market, by technology, 2018 - 2030 (USD Million)
  • Table 81 South Africa in vitro diagnostics (IVD) in cardiology and neurology market, by end-use, 2018 - 2030 (USD Million)
  • Table 82 Saudi Arabia in vitro diagnostics (IVD) in cardiology and neurology market, by product type, 2018 - 2030 (USD Million)
  • Table 83 Saudi Arabia in vitro diagnostics (IVD) in cardiology and neurology market, by technology, 2018 - 2030 (USD Million)
  • Table 84 Saudi Arabia in vitro diagnostics (IVD) in cardiology and neurology market, by end-use, 2018 - 2030 (USD Million)
  • Table 85 UAE in vitro diagnostics (IVD) in cardiology and neurology market, by product type, 2018 - 2030 (USD Million)
  • Table 86 UAE in vitro diagnostics (IVD) in cardiology and neurology market, by technology, 2018 - 2030 (USD Million)
  • Table 87 UAE in vitro diagnostics (IVD) in cardiology and neurology market, by end-use, 2018 - 2030 (USD Million)
  • Table 88 Kuwait in vitro diagnostics (IVD) in cardiology and neurology market, by product type, 2018 - 2030 (USD Million)
  • Table 89 Kuwait in vitro diagnostics (IVD) in cardiology and neurology market, by technology, 2018 - 2030 (USD Million)
  • Table 90 Kuwait in vitro diagnostics (IVD) in cardiology and neurology market, by end-use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 In vitro diagnostics (IVD) in cardiology and neurology market: market outlook
  • Fig. 14 In vitro diagnostics (IVD) in cardiology and neurology competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 In vitro diagnostics (IVD) in cardiology and neurology market driver impact
  • Fig. 18 In vitro diagnostics (IVD) in cardiology and neurology market restraint impact
  • Fig. 19 In vitro diagnostics (IVD) in cardiology and neurology market: Product type movement analysis
  • Fig. 20 In vitro diagnostics (IVD) in cardiology and neurology market: Product type outlook and key takeaways
  • Fig. 21 Instruments market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Reagents & consumables estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Software and services market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 In vitro diagnostics (IVD) in cardiology and neurology market: Technology movement analysis
  • Fig. 25 In vitro diagnostics (IVD) in cardiology and neurology market: Technology outlook and key takeaways
  • Fig. 26 Immunoassays market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Molecular diagnostics estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 Hematology market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 29 Others estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 30 In vitro diagnostics (IVD) in cardiology and neurology market: End-use movement analysis
  • Fig. 31 In vitro diagnostics (IVD) in cardiology and neurology market: End-use outlook and key takeaways
  • Fig. 32 Hospitals market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 33 Clinical laboratories estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 34 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 35 Global in vitro diagnostics (IVD) in cardiology and neurology market: Regional movement analysis
  • Fig. 36 Global in vitro diagnostics (IVD) in cardiology and neurology market: Regional outlook and key takeaways
  • Fig. 37 Global in vitro diagnostics (IVD) in cardiology and neurology market share and leading players
  • Fig. 38 North America, by country
  • Fig. 39 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 U.S. key country dynamics
  • Fig. 41 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Canada key country dynamics
  • Fig. 43 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 UK key country dynamics
  • Fig. 46 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Germany key country dynamics
  • Fig. 48 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 France key country dynamics
  • Fig. 50 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Italy key country dynamics
  • Fig. 52 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Spain key country dynamics
  • Fig. 54 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Denmark key country dynamics
  • Fig. 56 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Sweden key country dynamics
  • Fig. 58 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Norway key country dynamics
  • Fig. 60 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 62 China key country dynamics
  • Fig. 63 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 Japan key country dynamics
  • Fig. 65 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 66 India key country dynamics
  • Fig. 67 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 68 Thailand key country dynamics
  • Fig. 69 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 70 South Korea key country dynamics
  • Fig. 71 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 72 Australia key country dynamics
  • Fig. 73 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 74 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 75 Brazil key country dynamics
  • Fig. 76 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 77 Mexico key country dynamics
  • Fig. 78 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 79 Argentina key country dynamics
  • Fig. 80 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 81 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 82 South Africa key country dynamics
  • Fig. 83 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 84 Saudi Arabia key country dynamics
  • Fig. 85 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 86 UAE key country dynamics
  • Fig. 87 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 88 Kuwait key country dynamics
  • Fig. 89 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 90 Market share of key market players- In vitro diagnostics (IVD) in cardiology and neurology market